Relay Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference
Relay Therapeutics (Nasdaq: RLAY) will present at the 39th Annual J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Relay Therapeutics (Nasdaq: RLAY) will present at the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021, at 4:30 p.m. ET. The presentation will be available via a live webcast on Relay’s website, with an archived replay accessible for 30 days post-event. The company focuses on innovative drug discovery using its Dynamo platform, enhancing small molecule therapies targeting oncology. Relay Therapeutics aims to revolutionize the approach to previously challenging protein targets by utilizing advanced experimental and computational techniques.
Details
News Market Reaction – RLAY
The recorded move for RLAY in the trading session of this news was +4.24%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 4:30 p.m. ET. The presentation will be webcast live and may be accessed from the Investor page of Relay’s website under Events and Presentations. An archived replay of the webcast will be available for at least 30 days following the presentation.
About Relay Therapeutics
Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage precision medicines company transforming the drug discovery process with the goal of bringing life-changing therapies to patients. Built on unparalleled insights into protein motion and how this dynamic behavior relates to protein function, Relay Therapeutics aims to effectively drug protein targets that have previously been intractable, with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. The Company’s Dynamo platform integrates an array of leading-edge experimental and computational approaches to provide a differentiated understanding of protein structure and motion to drug these targets. For more information, please visit www.relaytx.com or follow us on Twitter.
Contact:
Pete Rahmer, Head of Investor Relations and Communications
617-322-0715
prahmer@relaytx.com
Media:
Dan Budwick
1AB
973-271-6085
dan@1abmedia.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.